Andrew Steinsapir

Andrew Steinsapir is the Acting Chief Technology Officer of Apertura Gene Therapy and Director, Gene Therapy Program Lead of Deerfield Management’s Discovery and Development team. Prior to Deerfield, Mr. Steinsapir was a Consultant for over three years at Dark Horse Consulting Group, where he provided strategic and tactical support for more than 30 cell and gene therapy firms, pharma, and investment firms. Previous to Dark Horse, Mr. Steinsapir worked at 4D Molecular Therapeutics, in several research and process development roles. Mr. Steinsapir holds a B.S. in Chemical Engineering with an emphasis on Biotechnology and an MBA from the University of California, Berkeley. Andrew is on the scientific advisory board for Jack’s Tomorrow, a foundation whose mission is to fund research to develop a treatment – and ultimately a cure – for PURA Syndrome.